Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC

Phase 2

Recruiting

• Conditions: Esophageal Squamous Cell Carcinoma Stage III; Esophageal Squamous Cell Carcinoma Stage II
• Interventions: Procedure: Neoadjuvant Chemoradiotherapy; Drug: Tislelizumab; Procedure: Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)

• Registration Number: NCT04973306
• Lead Sponsor: Shanghai Zhongshan Hospital

Brief Summary

The purpose of this study was to evaluate the safety, feasibility and outcome of anti-PD-1 antibody (Tislelizumab, BeiGene) combined with neoadjuvant chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by minimally invasive esophagectomy for locally advanced resectable esophageal squamous cell carcinoma (cII-III Stage) patient.

Detailed Description

It is a prospective randomized phase II\&III clinical trial sponsored by Shanghai Zhongshan Hospital with other twelve hospitals in China participating in. 476 patients with locally advanced resectable esophageal squamous cell carcinoma (cII-III Stage) are recruited and randomly assigned into the neoadjuvant chemoradiotherapy combined with immunotherapy group (nCRT plus anti-PD-1 Group) and the neoadjuvant chemoradiotherapy group (nCRT Group) according to the proportion of 1:1. The safety, efficacy of protocols and prognosis of patients are compared between the two regimens.

Study Timeline

• Study First Submitted: 2021-06-28
• Study First Submitted QC: 2021-07-13
• Study First Posted: 2021-07-22
• Study Start: 2022-03-02
• Status Verified: 2022-06
• Last Update Submitted: 2022-06-26
• Last Update Posted: 2022-06-30
• Primary Completion: 2024-07
• Study Completion: 2027-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 176

Inclusion Criteria

1. Histologically-confirmed esophageal squamous cell carcinoma and whose tissue samples were taken before treatment;
2. Tumors of the esophagus are located in the thoracic cavity;
3. Pre-treatment stage as clinical II-III (AJCC/UICC 8th Edition)
4. Age is between 18 years and 75 years;
5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and expected survival time ≥12 months;
6. Adequate cardiac function. All patients should perform ECG, and those with a cardiac history or ECG abnormality should perform echocardiography with the left ventricular ejection fraction > 50 %;
7. Adequate respiratory function with FEV1≥1.2L, FEV1%≥50% and DLCO≥50% shown in pulmonary function tests ;
8. Adequate bone marrow function (White Blood Cells >4x10^9 /L; Neutrophil >2.0×10^9 /L; Hemoglobin > 90 g/L; platelets>100x10^9 /L);
9. Adequate liver function (Total bilirubin <1.5x Upper Level of Normal (ULN); Aspartate transaminase(AST) and Alanine transaminase (ALT) <1.5x ULN);
10. Adequate renal function (Glomerular filtration rate (CCr) >60 ml/min; serum creatinine (SCr) ≤120 µmol/L);
11. The patient has provided written informed consent and is able to understand and comply with the study;

Exclusion Criteria

Exclusion Criteria associated with Cancer:

1. Patients with histological non-squamous cell carcinoma;

2. Patients with advanced non-operable or metastatic esophageal cancer;

3. Pre-treatment stage as cM+, cN3 or cT4b(non-curatively-resectable verified by the local surgical investigator, AJCC/UICC 8th Edition) or cTis-1a, cT1bN0;

4. Patients with another previous or current malignant disease which is likely to interfere with treatment or the assessment of response in the judgement of the local surgical investigator;

5. Patients who have received or are receiving other chemotherapy, radiotherapy or targeted therapy;

   Other Exclusion Criteria:

6. Patients with autoimmune diseases history;

7. Recently or currently taking Glucocorticoids or Immunosuppressants;

8. Patients who underwent immunotherapy in the past;

9. Allergy to any antibody drugs or allergy to Paclitaxel and Carboplatin.

10. Past or currently suffering from chronic or recurrent autoimmune diseases;

11. Patients with active infection of immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); HIV seropositivity; HBV DNA or HCV RNA positive;

12. Patients with organ transplantation (including autologous bone marrow transplantation and peripheral stem cell transplantation);

13. Patients with severe systematic intercurrent disease, such as active infection or poorly controlled diabetes; coagulation disorders; hemorrhagic tendency or under treatment of thrombolysis or anticoagulant therapy;

14. Any patient with a significant medical condition which is thought unlikely to tolerate the therapies. Such as cardiac disease (e.g. symptomatic coronary artery disease or myocardial infarction within last 12 months), clinically-significant lung disease, clinically-significant bone marrow, liver, renal function disorder;

15. Pregnant or lactating women and fertile women who will not be using contraception during the trial;

16. Participation in another intervention clinical trial with interference to the chemotherapeutic or chemoradiotherapeutic intervention during this study or during the last 30 days prior to informed consent;

17. Expected lack of compliance with the protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Neoadjuvant chemoradiotherapy combined with anti-PD-1 antibody	Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)	Neoadjuvant chemoradiotherapy (NCRT) combined with tislelizumab is performed followed by Ivor-Lewis or Mckeown esophagectomy in enrolled patients.
Neoadjuvant chemoradiotherapy combined with anti-PD-1 antibody	Neoadjuvant Chemoradiotherapy	Neoadjuvant chemoradiotherapy (NCRT) combined with tislelizumab is performed followed by Ivor-Lewis or Mckeown esophagectomy in enrolled patients.
Neoadjuvant chemoradiotherapy	Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)	Neoadjuvant chemoradiotherapy (NCRT) is performed followed by Ivor-Lewis or Mckeown esophagectomy in enrolled patients.
Neoadjuvant chemoradiotherapy	Neoadjuvant Chemoradiotherapy	Neoadjuvant chemoradiotherapy (NCRT) is performed followed by Ivor-Lewis or Mckeown esophagectomy in enrolled patients.
Neoadjuvant chemoradiotherapy combined with anti-PD-1 antibody	Tislelizumab	Neoadjuvant chemoradiotherapy (NCRT) combined with tislelizumab is performed followed by Ivor-Lewis or Mckeown esophagectomy in enrolled patients.

Primary Outcome Measures

Name	Time	Method
Pathological response rate(pCR)	Up to the date of pathological reports obtained since the date of randomization, up to 12 months	The resected specimen following neo-adjuvant treatment are assessed by using standardized work up of the resection specimen in the pathology department and standardized histological criteria for tumor regression grading. The degree of histomorphologic regression is clarified into four categories as follows: grade 1, no evidence of vital residual tumor cells (pathological complete response); grade 2, less than 10% vital residual tumor cells; grade 3, 10 to 50%; and grade 4, more than 50%.
Overall survival(OS)	Up to the date of death of any causes since the date of randomization, up to 36 months

Secondary Outcome Measures

Name	Time	Method
Number and Location of positive lymph nodes	Up to the date of pathological reports obtained since the date of randomization, up to 12 months	According to pathological reports, record the number and location of positive lymph nodes
Treatment related complications	Up to 1 month after surgery since the data of randomization, up to 13 months	Number and severity of adverse events that are related to treatment of each patients (including adverse events associated with neoadjuvant chemoradiotherapy, immunotherapy(irAE) and surgery), and hospital re-admission. Treatment-related adverse events as assessed by CTCAE v5.0
Progression-free survival(PFS)	Up to the date of disease recurrence since the date of randomization, up to 36 months	Disease recurrence is defined as locoregional (esophageal bed or anastomotic or regional lymph nodes) or metastatic (supraclavicular lymph nodes or distant organs)
R0 resection rate	Up to the date of pathological reports obtained since the date of randomization, up to 12 months	No vital tumor is presented at the proximal, distal, or circumferential resection margin, it is considered to be R0 resection. If a vital tumor is shown at 1 mm or less from the proximal, distal, or circumferential resection margin, it is considered to be microscopically positive (R1).
Overall Quality of life	Up to the end of follow-up since the data of surgery, up to 36 months	Overall Quality of life is respectively evaluated at randomization and 1 month, 3 month, 6 month and yearly after surgery among patients by using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30 Scale (EORTC QLQ-C30)
Quality of life in eating and swallowing function	Up to the end of follow-up since the data of surgery, up to 36 months	Quality of life in eating and swallowing function is respectively evaluated at randomization and 1 month, 3 month, 6 month and yearly after surgery among patients by using the EORTC QLQ-OES18 Scale
Recurrence-free survival (RFS)	Up to the date of disease recurrence since the date of surgery, up to 36 months	RFS is defined in resected patients who achieved an R0 or R1 resection as the time interval from surgery to the date of first recurrence (local, regional or distant) or death, whichever comes first.
Correlation between genetic profile and tumor response	Up to the end of follow-up since the data of surgery, up to 36 months	Genetic profile (assessed by whole exome sequencing, T-cell receptor sequencing, RNA sequencing) .illumina HiSeq and Nanostring platforms will be used to evaluate the patient's genetic profile. The tumor response will be evaluated by an experienced thoracic tumor pathologist in our center through Tumor regression grading (TRG) systems.

Trial Locations

Locations (1)

Shanghai Zhongshan Hospital; 🇨🇳 Shanghai, China